Announcements Trials
Browse Landscape

Status

Recruiting 3

Sponsor Class

INDUSTRY 3

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Classical hematology 1

Conditions

Myasthenia Gravis 3Neuromyelitis Optica 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Surveys and Questionnaires 543Blood Specimen Collection 447Surgical Procedures, Operative 165Observation 152Drug Therapy 143Radiotherapy 142Interviews as Topic 139Gene Expression Profiling 129Biopsy 117Magnetic Resonance Spectroscopy 116Immunohistochemistry 112Data Collection 95Polymerase Chain Reaction 87Specimen Handling 81Amplified Fragment Length Polymorphism Analysis 81Bevacizumab 79Microarray Analysis 76Flow Cytometry 69Neoadjuvant Therapy 68Watchful Waiting 67Magnetic Resonance Imaging 65Immune Checkpoint Inhibitors 62Nivolumab 60Immunotherapy 57Therapeutics 55Reverse Transcriptase Polymerase Chain Reaction 52pembrolizumab 50Ultrasonography 47Positron Emission Tomography Computed Tomography 47Hematologic Tests 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × ravulizumab × Clear all
NCT06909253 2026-05-15

MG-ARCADIA

AstraZeneca

Recruiting
50 enrolled

Myasthenia Gravis

NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

NCT06967480 2026-02-05

Early Ravulizumab Treatment Of Anti- AChR Antibody-Positive Generalized Myasthenia Gravis

Alexion Pharmaceuticals, Inc.

Recruiting
40 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon ⚔